[{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Children\u2019s Hospital Capital institute of Pediatrics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics","highestDevelopmentStatusID":"6","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Adipose Derived Mesenchymal Stromal Cell","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Inapplicable"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cellspan Esophageal Implant","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Harvard Apparatus Regenerative Technology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Study Phase : Phase I

                          Sponsor : Children’s Hospital Capital institute of Pediatrics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : The partnership aims to develop innovative treatments for Esophageal Atresia (EA) using our flagship Cellspan Esophageal Implant (CEI) product candidate.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Children’s Hospital Capital institute of Pediatrics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Adipose Derived Mesenchymal Stromal Cell,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          May 26, 2023

                          Lead Product(s) : Adipose Derived Mesenchymal Stromal Cell,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The FDA notified the Company that it removed the clinical hold and that the Company may proceed with its study.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 20, 2020

                          Lead Product(s) : Cellspan Esophageal Implant,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank